Breathe Well Live Well
Pharmaceutical Processing |
Diverse asthma treatment pipeline presents major investment opportunity
Pharmaceutical Processing The active and diverse treatment pipeline for asthma boasts a striking level of innovation, with many first-in-class products representing significant investment opportunities, says business intelligence provider GBI Research. The company's latest … |
View full post on asthma – Google News
|
Diverse Asthma Treatment Pipeline Presents Major Investment Opportunity, says …
Drug Discovery & Development The company's latest report* states that while asthma therapy development is dominated by small molecule compounds, with 156 products representing 67% of the pipeline, the research and development landscape has moved towards biologics on an … |
View full post on asthma – Google News
|
Boehringer Presents New Phase III Data for Asthma Therapy Tiotropium
Lung Disease News Boehringer Ingelheim Pharmaceutical company Boehringer Ingelheim recently presented encouraging data regarding its investigational drug tiotropium delivered through the company's Respimat inhaler, for the treatment of asthma. The data was presented … Tiotropium improves lung function in asthma, regardless of allergic status |
View full post on asthma – Google News
|
Utah Asthma Coalition presents proposals for Logan schools
The Herald Journal Bennion explained that last year in the United States, 2 million kids ended up in the ICU because of asthma and 5 million went to an emergency room. However, only 27 percent of asthmatics receive adequate care. This is due to several factors, he said, … |
View full post on asthma – Google News
|
Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma …
Drug Discovery & Development Boehringer Ingelheim announced new data from large scale, Phase 3 studies showing that once-daily tiotropium delivered via the Respimat inhaler was effective and well tolerated in patients across asthma severities. These data were presented at the … Tiotropium as Asthma Add-On Treatment Shows Promise |
View full post on asthma – Google News
|
Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma …
PR Newswire (press release) RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ — Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat® inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, … |
View full post on asthma – Google News
|
Boehringer Ingelheim presents positive efficacy data for tiotropium in asthma …
The Pharma Letter German family-owned drug major Boehringer Ingelheim presented a new subset of data from the Phase III UniTinA-asthma program relating to its already-marketed drug Spiriva (tiotropium) at the 2013 American Academy of Allergy, Asthma & Immunology … Boehringer Ingelheim drug shows benefits in new asthma trial |
View full post on asthma – Google News
|
Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic …
PR Newswire (press release) SAN ANTONIO, Feb. 23, 2013 /PRNewswire/ — Boehringer Ingelheim presented today a new subset of data from the Phase III UniTinA-asthma™ program at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San … |
View full post on asthma – Google News
|
Ask Dr. K: Asthma med presents risk low for osteoporosis Asthma med risk low …
Monterey County Herald Dear Dr. K: Could my asthma medication have caused my osteoporosis? What about other drugs? Dear Reader: As you know, osteoporosis is a disease that weakens bones and makes them break more easily. Some asthma treatments can increase your risk for … |
View full post on asthma – Google News
|
Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with …
PR Newswire (press release) Boehringer Ingelheim announced that a comprehensive confirmatory Phase III trial program named UniTinA-asthma™ is ongoing to fully evaluate the potential of the long-acting bronchodilator in the treatment of asthma in pediatric, adolescent and adult … Promising Phase II Data With Once-Daily Tiotropium may Lead to New Treatment … Results of Phase II Study of Boehringer Ingelheim's Investigational … |
View full post on asthma – Google News